cyrilzakka/clinical-trials huggingface dataset:
Observational Study on the Prevalence of Urinary Incontinence in Federates Athletes.

To study the prevalence of urinary incontinence (UI) in female athletes from Castilla y León, as well as the category of athletics with the highest number of losses, the most incident risk factors and the bio-psycho-social consequences that it leads to.

Elaboration of a survey, based on two validated questionnaires to which 63 participants have answered, to carry out an analytical, transversal and observational study. All the participants are women, of age, federated in athletics and belonging to Castilla y León.

UI has a high prevalence (44.4%) in female athletes, being more common in those who practice long-distance races. As age and years of sport increase, the incidence of this pathology increases. Absorbent pads are used by more than half of the incontinent women, while the rest wet their underwear. Menopause, childbirth and surgery in the region are risk factors for UTIs, while the presence of urinary tract infections or candidiasis are not. The results affirm that urine leaks do not cause anxiety or depression, but they do affect your sporting life.

Eligibility Criteria:
Inclusion Criteria:

* Female sex.
* Adulthood.
* Federated in athletics.

Exclusion Criteria:

* Men.
* Those women who are no longer federated or who are minors.
Cognition and QoL After Thyroid Surgery

The development of cognitive dysfunction can profoundly affect HR-QoL as well as the possibility of societal participation and ability to work, and thereby relevantly impacts prospects for cancer survivorship. The aim of the study is to obtain improved understanding of the scope and magnitude of objective cognitive dysfunction in DTC survivors, and its relation to subjective cognitive dysfunction, thyroid hormone levels, physical activity and HRQoL. This is done in a prospective study where patients operated for a thyroid nodule (Bethesda IV-VI, i.e., benign \[goitre with nodule and fibroadenomas\], low-risk DTC and intermediate-high risk DTC) are included and asked to serially perform online neuropsychological testing as well as to complete questionnaires related to HR-QoL, physical activity and additional psychological and physical complaints. Blood is analysed for levels of thyroid hormones and systemic inflammation.

The primary aim of this study is to prospectively assess objective cognitive functioning in patients undergoing thyroid surgery for different indications by means of an online neuropsychological test, the Amsterdam Cognition Scale (ACS).

Three patient groups are defined; 1) patients with follicular adenomas, 2) patients with extreme low-risk differentiated thyroid cancer (DTC; pT1a and pN0/x tumours), 3) patients in all other DTC risk groups (i.e., low, intermediate and high-risk). The primary comparison confers to groups 1 and 3.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years old, indication for surgery because of a thyroid nodule Bethesda IV-VI
* Able to read and understand the Swedish language
* Access to desktop computer or laptop with internet connection
* Able and willing to provide written informed consent

Exclusion Criteria:

* A previous diagnosis of (auto-immune) hypothyroidism
* A previous cancer diagnosis (excluding basal cell cancer of the skin)
* Indications for surgery other than (solely) a thyroid nodule (i.e., concomitant Graves)
* A diagnosis of medullary and anaplastic thyroid cancer
Daily Magnesium-supplement for Severe Asthmatics

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to reveal possible beneficial effects of daily magnesium supplement for severe asthmatics, refractory to conventional treatment.


Eligibility Criteria:
Inclusion Criteria:

* severe asthmatics, refractory to conventional treatment, including systemic steroid treatment; symptoms must be annual.

Exclusion Criteria:

* Se-Mg \> 2,00 mmol/L,
* smoking cessation less than 1 year prior to study start,
* major changes in eating habits within three months prior to study start and during the study period of approximately one year,
* various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.
Insulin-based Strategies to Prevent Hypoglycemia During Exercise

It has been reported that insulin basal rate reduction initiated at exercise onset can reduce the hypoglycemic risk during exercise. However, another potentially more efficient strategy to prevent exercise-induced hypoglycemia could be to reduce insulin basal rate a certain time prior to exercise. The objective of this study will be to compare the efficacy of two strategies to prevent exercise-induced hypoglycemia during a 60-minute exercise at moderate intensity: 1) reduce insulin basal rate 40 minutes prior to exercise; 2) reduce insulin basal rate 90 minutes prior to exercise.


Eligibility Criteria:
Inclusion Criteria:

1. Males and females ≥ 14 years of old.
2. Clinical diagnosis of type 1 diabetes for at least two years.
3. The subject will have been on insulin pump therapy for at least 3 months.
4. Last (less than 2 months) HbA1c ≤ 10%.

Exclusion Criteria:

1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy or severe proliferative retinopathy as judged by the investigator.
2. Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
3. Abnormal blood panel and/or anemia.
4. Ongoing pregnancy.
5. Severe hypoglycemic episode within two weeks of screening.
6. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).
7. Failure to comply with team's recommendations (e.g. not willing to change pump parameters, etc.).
Genetic Predictors of Incident Cardiovascular Disease

To evaluate how current genetic information about cardiovascular disease susceptibility genes contributes to the prediction of future cardiovascular disease outcomes.

BACKGROUND:

During the 1980s and 1990s, genetic research in cardiovascular disease (CVD), as well as other common chronic diseases, has been dominated by single gene linkage and association studies focused on understanding of the genetics of prevalent disease. Rarely have there been studies of the longitudinal predictive value of these genetic variations. Furthermore, few studies have attempted to address the complex and high-dimensional genetic reality that underlies an individual's risk of disease. A crucial next step in CVD genetic research is the evaluation of the contribution of variations in many genes simultaneously, and their interactions with traditional risk factors, to the longitudinal prediction of CVD in individuals and families.

DESIGN NARRATIVE:

The study uses participants from the Rochester Family Heart Study (RFHS) which provides one of the richest genetic epidemiological resources for this type of study. The RFHS represents 3941 individuals distributed among 552 three- generation pedigrees ascertained without regard to health status during two phases of collection. Phase I was from 1984 - 1988 and Phase II was from 1988 - 1991. These participants have extensive demographic, physiological, genetic, and clinical information measured at baseline. This study builds upon this already established resource by conducting a longitudinal follow-up of the RFHS participants to address two central questions: 1) Do measured genetic variations in known susceptibility genes provide additional predictive information about risk of future CVD outcomes beyond the information provided by more traditional risk factors? and 2) Do these measured genetic variations explain patterns of disease aggregation in families and can these patterns be used to predict disease in future generations?

Eligibility Criteria:
No eligibility criteria
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI).

Participants will take Epidiolex (purified CBD) for 90 days

This pilot study assesses the feasibility of using 100mg of twice daily cannabidiol (Epidiolex) in adult spinal cord injury with neurogenic lower urinary tract dysfunction following resolution of spinal shock.

Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* History of supra-sacral spinal cord injury of any mechanism
* Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
* Willingness to participate in drug intervention trial
* English-speaking (able to provide consent and complete questionnaires)

Exclusion Criteria:

* History of intravesical Botox
* Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
* Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
* Thought or mood disorder aside from depression
Intraoperative Dexamethasone and Its Effect on Hyperglycemia

To study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.


Eligibility Criteria:
Inclusion Criteria:

* documented history of Type I or Type II Diabetes Mellitus
* scheduled for surgery that requires patients to be admitted for at least 24 hours post-surgery

Exclusion Criteria:

* Patients on steroid therapy
* Pregnant women
* Patients at low risk for nausea/vomiting
Chronic Low Back Pain Graded - Exposure Psychoeducation Intervention

This study will examine the effectiveness of one of two psychoeducation treatments on chronic low back pain.

This study will examine the effectiveness of one of two psychoeducation treatments on chronic low back pain. Participants will be randomized to one of these two treatments.

Eligibility Criteria:
Inclusion Criteria:

* report having low back pain for more than three months and at least half the days in the past 6 months
* be 18-65 years of age,
* have scores higher than 37 on the Tampa Scale of Kinesiophobia,

Exclusion Criteria:

* medical conditions other than back pain that significantly impair movement (e.g., arthritis)
* confirmed/suspected pregnancy
* pending litigation related to an episode of low back pain
* significant impairment in vision
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

Obtain interaction data between BI 201335 and Efavirenz to guide dosing for each drug when administered together.

To predict drug interaction between BI 201335 and Cyp 3A4 y using Midazolam as cyp 3A4 probe , Efavirenz as enzyme inducer and BI 201335 as enzyme inhibitor.


Eligibility Criteria:
Inclusion criteria:

Healthy volunteers age 18- 55 BMI (Body Mass Index) 18.5 - 29.9

Exclusion criteria:

1. Any finding on medical examination and ECG (Electrocardiography) deviating from normal
2. Active diseases
3. History of photosensitivity or rash
Effects of Melatonin in PCOS Women

The aim of our study is to investigate the effects of a treatment with melatonin on clinical, endocrine and metabolic features in women affected by PCOS. The study group included 40 patients treatend with 2 mg of melatonin daily for six months. Menstrual pattern, anthropometric parameters, hirsutism score, ultrasound ovarian volume and antral follicular count, an oral glucose tollerance test and hormonal assays are evaluated before and after therapy.


Eligibility Criteria:
Inclusion Criteria:

* women with PCOS in accordance with Rotterdam criteria

Exclusion Criteria:

* pregnancy
* past history of cardiovascular diseases
* diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 gr oral glucose tolerance test)
* hypertension
* significant liver or renal impairment
* other hormonal dysfunction (hypothalamic, pituitary, thiroidal or adrenal)
* neoplasms
Self-Care Management in Chronic Disease

Self-management of chronic diseases includes treatment and adoption of healthy behaviors. The research was planned to determine the effect of health education on disease management in the elderly with chronic diseases. The research will be conducted in a parallel group, randomized controlled manner. Older adults will receive 6 weeks of health education. After the training, the scales will be re-administered face to face or online.


Eligibility Criteria:
Inclusion Criteria:

* Being in the 65-75 age group,
* Having a chronic disease

Exclusion Criteria:

* Having vision and hearing problems
* Being 76 or older
* Having a neuro-psychiatric disease
The Effect of Cognitive Behavior Intervention on Psychological Distress of Cancer Patients and Their Family Members

The aim of the study is to evaluate the effect of cognitive behavior group intervention with cancer patients and their family members. Around 80 cancer patients and their family members will participate in group intervention and will be compared with 80 controls.

The aim of the study is to evaluate the effect of cognitive behavior group intervention with cancer patients and their family members. Around 80 cancer patients and their family members will participate in group intervention and will be compared with 80 controls (randomized control study). Brief Symptom Inventory,Fatigue inventory, Mini Sleep Questionnaire and repression-sensitization questionnaire will be answered by the participants pre-, post-intervention and after four months.

Eligibility Criteria:
Inclusion Criteria:

* Hebrew speaking

Exclusion Criteria:

* psychiatric condition
AVTX-801 D-galactose Supplementation in SLC35A2-CDG

This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG


Eligibility Criteria:
Inclusion Criteria

* Molecular confirmation of SLC35A2 genetic variant
* Age \> 1 month
* Presence of seizures, chronic vomiting, chronic constipation, or chronic diarrhea
* A parent or legal guardian must be available and willing to provide consent on behalf of minor subjects or adult subjects who are unable to give informed consent due to developmental disabilities.
* Use of contraception in females \> age 8 years
* Previously performed eye exam within last year

Exclusion Criteria

* Aldolase-B deficiency
* Galactosemia
* Hemolytic uremic syndrome
* Hemoglobin \< 7 mg/dL
* LFTs \> 3x ULN
* Previously experienced severe AEs from oral galactose (severe diarrhea, vomiting, constipation, galactosuria, or increased liver glycogen storage)
* Other history of galactose intolerance as determined by the investigator
* Currently treated with ketogenic diet
* Current enrollment in another trial involving investigational compounds
* Ongoing dietary D-galactose supplementation
* Use of investigational compounds
* Pregnancy
A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

The purpose of this study is to help us learn what is the best amount of fluid to give to patients during bladder surgery in order to avoid delayed bowel function after surgery, which could prolong hospital stay.


Eligibility Criteria:
Inclusion Criteria:

* Adults (21 years old or greater) who are able to provide informed consent
* Patients who undergo an open, elective radical cystectomy

Exclusion Criteria:

* Patients with active atrial fibrillation or flutter, since the algorithm is not accurate in case of cardiac arrhythmia
* Female patients who are pregnant (female patients of child-bearing potential must have a negative serum pregnancy test ≤ 14 days prior to surgery or 15 to 30 days prior to surgery with a negative urine pregnancy test the morning of surgery)
* Presence of ascites, because increased abdominal pressure interferes with EV1000 reading accuracy
* BMI \> 45 or \<17, because increased abdominal pressure interferes with EV1000 reading accuracy
Effects of Electromyography-Triggered Constraint-Induced Movement Cycling Therapy on Patients With Chronic Stroke

The study investigates the potential of Electromyography (EMG)-triggered Constraint-Induced Movement Cycling Therapy (CIMCT) versus General Cycling Training (GCT) to enhance balance, strength, and daily activities in chronic stroke patients. Over a period of four weeks, this single-blind randomized controlled trial aims to explore how these interventions can assist in stroke rehabilitation. The research has been approved by the Ethics Committee of Kyungdong University and adheres to the ethical standards laid out in the Declaration of Helsinki.

This research evaluates the effectiveness of EMG-triggered CIMCT in improving balance, lower extremity strength, and activities of daily living (ADLs) for chronic stroke patients with hemiplegia, a condition typically resulting from a stroke. The study's scope includes:

Duration and Type: A four-week, single-blind randomized controlled trial. Participants: Chronic stroke patients diagnosed with stroke-induced hemiplegia for more than six months, possessing specific levels of cognitive and motor recovery.

Interventions: Participants are randomly assigned to one of two groups:

CIMCT Group: Utilizes an EMG-triggered Constraint-Induced Movement Therapy device designed to engage the affected lower extremity actively.

GCT Group: Engages in activity using a standard stationary bicycle without EMG facilitation.

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic stroke-induced hemiplegia
* Diagnosed with stroke for more than 6 months
* Achieving a minimum score of 24 points on the Mini-Mental State Examination
* Demonstrating motor recovery at or above level 3 according to the Brunnstrom stages

Exclusion Criteria:

* Individuals with neurological damage unrelated to their stroke
* Orthopedic issues such as fractures or peripheral nervous system damage in the lower limbs
* Visual or auditory impairments
* Those who had experienced more than one stroke
* Those with less than an 80% participation rate in the study
A Study on a Blood-based Dual-target Test for CRC Detection

To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.

Usually, colorectal cancers (CRCs) diagnosed in their early stages are curable, especially precancerous lesions (adenomas, polyps) that can be removed during a colonoscopy.However, due to low patient compliance and limited resources, colonoscopy is not feasible for screening the average-risk population. gFOBT/FIT are limited by their low sensitivity and high false-positive rate. Compared to colonoscopy and stool DNA tests, blood-based methylation tests showed greater patient compliance and convenience. Hypermethylated NTMT1 and MAP3K14-AS1 were found in multiple cohorts of CRC samples in our previous study. In this study, we aimed to evaluate the effectiveness and accuracy of the ctDNA dual-target(NTMT1 and MAP3K14-AS1) test kit in 5 tertiary hospitals around china for the detection of colorectal cancer and advanced adenomas. Fecal immunochemical test (FIT) will also privided to participants in the study. Sanger sequencing would be performed to evalute the accuracy of the dual-target methylation detection test kit.

Eligibility Criteria:
Inclusion Criteria:

1. Inclusion Criteria for CRC group（≥30%） 1)Patients with colorectal cancer 2)Follow-up sample subjects: Subjects who underwent resection of colorectal cancer lesions.
2. Inclusion Criteria for Control group（≤70%） Health volunteer, or subject with other diseases or physiological conditions other than colorectal cancer, including but not limited to gastritis, gastric cancer, esophagitis, rheumatoid arthritis, prostate cancer, microbes (inflammation patients), gastrointestinal bleeding, drugs (typical digestive tract medication) Population), neuroendocrine cancer, squamous cell carcinoma (squamous squamous cell carcinoma, esophageal squamous cell carcinoma);

Exclusion Criteria:

1. Patients who had undergone radical resection of bowel cancer (except for postoperative follow-up) and those who had received anti-tumor therapy such as radiotherapy/chemotherapy；
2. Colorectal cancer or colorectal adenoma with other malignancies；
3. Postoperative follow-up patients of colorectal cance with distant metastasis;
4. The sample size collected did not meet the detection requirements;
5. Other patients who are considered unsuitable for this study (such as pregnancy, high blood pressure, heart disease, etc., who are not suitable for colonoscopy due to physical condition).
Evaluating Vitamin D Content in Mushrooms

This study will evaluate how much vitamin D is present in a mushroom supplement. This supplement contains an extract from mushrooms that have been exposed to sunlight. The mushroom supplement will be compared to non-commercially available vitamin D supplements produced in a Goo Manufacturing Practices (GMP)-licensed facility.

Mushrooms have the capability to produce vitamin D in a similar way to human skin. When exposed to ultraviolet light, mushrooms will convert a precursor to vitamin D. This reaction produces large amounts of vitamin D. This study is comparing a natural source of vitamin D to a synthetic source of vitamin D and will help determine if mushrooms are a novel source for this essential nutrient.

Eligibility Criteria:
Inclusion Criteria:

* All healthy adults, male and female, age 18-64 years

Exclusion Criteria:

* Currently taking, or having taken less than one month prior to start of study, a prescription of 50,000 IU of vitamin D2 or 2000 IU vitamin D2 or vitamin D3
* Allergy to mushrooms
* History of elevated calcium (\>10.4 mg%)
* Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
* Supplementation with over the counter formulations of vitamin D2 or vitamin D3
* Subjects with a history of an adverse reaction to orally administered vitamin D.
* Subjects who are taking oral Dilantin or glucocorticoids.
* Exposure to a tanning bed or tanning on a beach for more than eight hours with no sunscreen within 2 weeks prior to start of study.
* History of intestinal malabsorption (i.e. cystic fibrosis, fat malabsorption syndrome, Crohn's Disease, gastric bypass surgery).
* Subjects with any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study.